Korean firm HLB has signed a memorandum of understanding with Nanogen Pharmaceutical Biotechnology JSC, producer of Vietnam's Nano Covax COVID-19 vaccine candidate, to acquire the rights to distribute the vaccine worldwide, except in Vietnam and India, when the vaccine is approved for use.

VOV.VN - Indian firm Vekaria Healthcare LLP and Nanogen Pharmaceutical Biotechnology JSC, the Vietnamese developer of Nano Covax vaccine against COVID-19 have signed a non-disclosure agreement (NDA) on the transfer of technology to produce the vaccine.

VOV.VN - Approximately 10,000 vials of Remdesivir, a broad-spectrum antiviral drug licensed by the US Food and Drug Administration (FDA) for COVID-19 treatment arrived in Vietnam on August 5 evening.

VOV.VN - Some of big Indian pharmaceutical companies have agreed to provide Vietnam with approximately 1 million doses of Remdesivir, a broad-spectrum antiviral medication, for COVID-19 treatment.

VOV.VN - One million doses of Vero Cell vaccine arrived in Ho Chi Minh City on July 31 as part of a deal to import five million doses of the vaccine from Chinese pharmaceutical company Sinopharm.

A group of 30 pharmaceutical production companies from India plans to build the first Pharma Park in Vietnam, and Da Nang city’s Hi-tech Park has been suggested as a prime location.

VOV.VN - The Ministry of Health has permitted a pharmaceutical company of Ho Chi Minh City to purchase five million doses of China’s Sinopharm COVID-19 vaccine known as Vero Cell for emergency use.

VOV.VN - A further 219 people, including 9 entrants to the country, tested positive for the SASR-CoV-2 virus on the evening of July 2, thereby lifting the daily infection count to 545, according to figures given by the Ministry of Health.

VOV.VN - A further 43 local COVID-19 cases and one imported infection were recorded on June 8 morning, with current hotspots of Bac Ninh, Bac Giang and Ho Chi Minh City taking the most, according to data released by the Health Ministry.

VOV.VN - Nanogen Pharmaceutical Biotechnology JSC have announced plans to launch the third phase of human trials for its locally-produced coronavirus vaccine Nano Covax on May 5, a timeframe which is three months ahead of schedule.